Rosacea – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Rosacea – Pipeline Review, H2 2016’, provides an overview of the Rosacea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rosacea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rosacea

The report reviews pipeline therapeutics for Rosacea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rosacea therapeutics and enlists all their major and minor projects

The report assesses Rosacea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rosacea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rosacea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Amorepacific Corporation

Cell Medica Limited

Cutanea Life Sciences Inc

Foamix Pharmaceuticals Ltd.

Hovione FarmaCiencia SA

Merz Pharma GmbH & Co. KgaA

Promius Pharma, LLC

Sol-Gel Technologies Ltd.

TWi Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Rosacea Overview 8

Therapeutics Development 9

Pipeline Products for Rosacea - Overview 9

Rosacea - Therapeutics under Development by Companies 10

Rosacea - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Rosacea - Products under Development by Companies 14

Rosacea - Companies Involved in Therapeutics Development 15

Allergan Plc 15

Amorepacific Corporation 16

Cell Medica Limited 17

Cutanea Life Sciences Inc 18

Foamix Pharmaceuticals Ltd. 19

Hovione FarmaCiencia SA 20

Merz Pharma GmbH & Co. KgaA 21

Promius Pharma, LLC 22

Sol-Gel Technologies Ltd. 23

TWi Pharmaceuticals, Inc. 24

Rosacea - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

AC-701 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ACUD-1 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

B-244 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

benzoyl peroxide - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

brolucizumab - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CLS-005 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

DFD-29 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

DMT-200 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

DMT-210 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

DMT-220 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

FMX-103 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

incobotulinumtoxin A - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

itraconazole - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

minocycline - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

omiganan pentahydrochloride - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

oxymetazoline hydrochloride - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

PAC-14028 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Rosacea - Dormant Projects 59

Rosacea - Discontinued Products 61

Rosacea - Product Development Milestones 62

Featured News & Press Releases 62

Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 62

Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea 62

Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea 63

May 24, 2016: Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream

1.0% 63

May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea 64

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 64

May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea 65

Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 65

Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 66

Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 66

Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 67

Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 68

Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 68

Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 69

Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 70

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72List of Tables

Number of Products under Development for Rosacea, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Rosacea - Pipeline by Allergan Plc, H2 2016 15

Rosacea - Pipeline by Amorepacific Corporation, H2 2016 16

Rosacea - Pipeline by Cell Medica Limited, H2 2016 17

Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2016 18

Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19

Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2016 20

Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 21

Rosacea - Pipeline by Promius Pharma, LLC, H2 2016 22

Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2016 23

Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Rosacea - Dormant Projects, H2 2016 59

Rosacea - Dormant Projects (Contd..1), H2 2016 60

Rosacea - Discontinued Products, H2 2016 61

List of Tables

List of Tables

Number of Products under Development for Rosacea, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Rosacea – Pipeline by Allergan Plc, H2 2016 15

Rosacea – Pipeline by Amorepacific Corporation, H2 2016 16

Rosacea – Pipeline by Cell Medica Limited, H2 2016 17

Rosacea – Pipeline by Cutanea Life Sciences Inc, H2 2016 18

Rosacea – Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19

Rosacea – Pipeline by Hovione FarmaCiencia SA, H2 2016 20

Rosacea – Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 21

Rosacea – Pipeline by Promius Pharma, LLC, H2 2016 22

Rosacea – Pipeline by Sol-Gel Technologies Ltd., H2 2016 23

Rosacea – Pipeline by TWi Pharmaceuticals, Inc., H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Rosacea – Dormant Projects, H2 2016 59

Rosacea – Dormant Projects (Contd..1), H2 2016 60

Rosacea – Discontinued Products, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Rosacea, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports